About immunic inc. - IMUX
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.
IMUX At a Glance
Immunic, Inc.
1200 Avenue of the Americas
New York, New York 10036
| Phone | 1-332-255-9818 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -97,172,000.00 | |
| Sector | Health Technology | Employees | 92 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
IMUX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.662 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.008 |
IMUX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,056,217.391 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
IMUX Liquidity
| Current Ratio | 0.747 |
| Quick Ratio | 0.747 |
| Cash Ratio | 0.506 |
IMUX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -299.359 |
| Return on Equity | -1,653.147 |
| Return on Total Capital | 1,594.029 |
| Return on Invested Capital | -1,602.573 |
IMUX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -9.465 |
| Total Debt to Total Assets | 2.399 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -1.755 |